Treatment of cancer with immune stimulators
AssigneeSciClone Pharmaceuticals, Inc.
InventorsRobert S. KING, Cynthia W. TUTHILL, Friedhelm BLOBEL
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.
Claims45
A method of treating cancer or a metastasis thereof in a subject comprising administering a composition comprising therapeutically effective amount of a first immune stimulator and a second immune stimulator, wherein the first immune stimulator is an alpha thymosin peptide, and the second immune stimulator is a compound other than IL-2, interferon-α, or IRX-2.
A method of treating cancer or a metastasis thereof in a subject comprising administering a composition comprising therapeutically effective amount of an immune stimulator, wherein the immune stimulator is effective in treating sepsis.
The method of 30, wherein the cancer is melanoma.
A method for determining the responsiveness of a human subject to cancer treatment comprising determining the level of activity of one or more biomarkers in a biological sample from a human subject, wherein the biomarkers are selected from the group consisting of IL-1β, IL-4, IL-6, and IL-10.
The method of 39, wherein the cancer is melanoma.
Dependencies are inferred from the claim text.